Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests reduced post surgery (adjuvant) therapy for patients with early breast cancer who have confirmed that the disease has responded completely (pathologic complete response) after pre surgical treatment (neoadjuvant) therapy and do not have any tumor genetic material (molecular residual disease) circulating in their blood. Standard of care treatment after surgery consists of 1 year of pembrolizumab for patients with triple negative breast cancer or trastuzumab with or without pertuzumab to complete 1 year of treatment. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Pertuzumab and trastuzumab are monoclonal antibodies and forms of targeted therapy that attach to a receptor protein called HER2. HER2 is found on some cancer cells. When pertuzumab or trastuzumab attach to HER2, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Lowering the total amount of cancer therapy after breast surgery, may continue to keep the great tumor response to treatment, and may help lower the amount of side effects patients have.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci z wczesnym rakiem piersi HER2+ lub potrójnie ujemnym (TNBC).
- •Rak piersi potwierdzony w biopsji.
- •U pacjentek z HER2+ choroba całkowicie ustąpiła po leczeniu przedoperacyjnym i nie wykryto krążącego materiału genetycznego guza we krwi.
- •U pacjentek z potrójnie ujemnym rakiem (TNBC) zastosowano wcześniej terapię z lekiem pembrolizumab i chemioterapią.
- •Pacjenci muszą wyrazić zgodę na potencjalne zmniejszenie dawki standardowego leczenia po operacji.
✗ Disqualifies
- •Pacjenci z przerzutami raka piersi do innych narządów.
- •Pacjenci, u których choroba nie ustąpiła całkowicie po leczeniu przedoperacyjnym.
- •Pacjenci, u których wykryto krążący materiał genetyczny guza we krwi po leczeniu przedoperacyjnym (dotyczy grupy HER2+).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
M D Anderson Cancer Center
Houston, United States
Trial contact
Vicente Valero, MD
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.